UK Children to Receive Chickenpox Vaccine for the First Time via Combined MMRV Jab
Table of Contents
A new era in childhood disease prevention begins as the UK introduces a combined measles, mumps, rubella, and chickenpox (MMRV) vaccine for all young children, offering crucial protection and easing the financial burden on families.
For the first time, all young children in the United Kingdom will be offered routine vaccination against chickenpox through the National Health Service (NHS). The new vaccine, known as MMRV – with the “V” representing varicella, the medical term for chickenpox – will be administered alongside the existing MMR jab at 12 and 18 months of age. A comprehensive catch-up program will also extend the offer to children up to the age of six.
A Long-Awaited Step Towards Comprehensive Protection
Until now, parents seeking to protect their children from the highly contagious and potentially serious effects of chickenpox faced private vaccine costs of up to £200. The introduction of MMRV into the standard childhood vaccination schedule in England, Wales, and Northern Ireland, beginning January 1st, marks a significant shift in public health policy. Scotland is set to follow suit with a rollout commencing in early January.
Chickenpox, characterized by an intensely itchy, blistering rash, is a common childhood illness. While typically mild, the infection can cause significant discomfort, covering the entire body and often accompanied by fever and muscle aches. Approximately 90% of children under the age of 10 will contract chickenpox, frequently resulting in a week of absence from school or nursery.
However, the illness can escalate into more severe complications, particularly for vulnerable populations. “For some babies, young children and even adults, chickenpox can be very serious, leading to hospital admission and tragically, while rare, it can be fatal,” warned Dr. Gayatri Amirthalingam, deputy director of immunisation at the UK Health Security Agency. These complications include bacterial infections of the scabs, encephalitis (swelling of the brain), pneumonitis (lung inflammation), and, in rare cases, stroke. Young infants, adults, and pregnant women are at heightened risk of severe illness.
A Mother’s Plea: The Devastating Consequences of Chickenpox
The potential severity of chickenpox is tragically illustrated by the story of Beth Horton, who suffered a stroke weeks after contracting the virus at the age of two-and-a-half. Her mother, Maria Horton, shared her heartbreaking experience: “She collapsed and her arm and leg went all floppy and then she started to have a seizure.” Beth now lives with lasting disabilities, including impaired use of her right hand and speech difficulties, alongside chronic pain.
“I know some people are hesitant about vaccines but if I’d known years ago what I know now, I wouldn’t hesitate to give her the vaccine,” Ms. Horton stated. “As a mum, if you could go back in time and stop something catastrophic happening to them, you absolutely would. And if I could prevent somebody else from going through what Beth did, that would be amazing.”
Economic and Public Health Benefits of the MMRV Rollout
The decision to introduce the MMRV vaccine follows years of debate, initially hampered by concerns over cost and a potential increase in shingles cases. However, experience from countries like the United States, Canada, Australia, and Germany – where the MMRV vaccine has been safely used for decades – demonstrates a reduction in both chickenpox incidence and severe complications.
The vaccine itself is highly effective, providing approximately 97% protection after two doses. Furthermore, recent research highlights the substantial economic impact of chickenpox in the UK. NHS England estimates that the illness results in £24 million in lost income and productivity annually. The rollout of the MMRV vaccine is projected to save £15 million per year in NHS treatment costs.
“Families will save both time and money – no longer facing lost income from taking time off work or having to fork out for private vaccinations,” explained Health Secretary Wes Streeting. Dr. Claire Fuller, NHS England’s national medical director, hailed the move as “a hugely positive moment for children and their families.”
Vaccination Schedule and Eligibility
The MMRV vaccine will replace the current MMR jab for children born after January 1, 2026, with two doses administered at 12 and 18 months. A phased catch-up program will ensure older children also receive protection:
- Born on or after January 1, 2025: Two doses, at 12 and 18 months.
- Born between July 1, 2024, and December 31, 2024: Two doses, at 18 months and 3 years and 4 months.
- Born between September 1, 2022, and June 30, 2024: One dose at 3 years and 4 months.
- Born between January 1, 2020, and August 31, 2022: A single dose will be offered later in 2026.
- Aged six or older on December 31, 2025: Not eligible, as they are likely to have already contracted chickenpox.
GP surgeries will proactively contact families to schedule appointments. The Royal College of Paediatrics and Child Health and the Royal College of GPs have both affirmed the safety and efficacy of all NHS childhood vaccines, emphasizing their critical role in protecting children’s health. This landmark decision represents a significant step forward in safeguarding the health and well-being of future generations in the UK.
